Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

ग्रंथसूची विवरण
मुख्य लेखकों:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
स्वरूप:	Conference item
भाषा:	English
प्रकाशित:	European Respiratory Society 2020

समान संसाधन

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
द्वारा: Moran, AM, और अन्य
प्रकाशित: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
द्वारा: Shrimanker, R, और अन्य
प्रकाशित: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
द्वारा: Charlene Desaintjean, और अन्य
प्रकाशित: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
द्वारा: Bel, E, और अन्य
प्रकाशित: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
द्वारा: Andrea Portacci, और अन्य
प्रकाशित: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
द्वारा: Bel, E, और अन्य
प्रकाशित: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
द्वारा: S. K. Zyryanov, और अन्य
प्रकाशित: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
द्वारा: Pavord, I, और अन्य
प्रकाशित: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
द्वारा: Arian Ghassemian, और अन्य
प्रकाशित: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
द्वारा: Pavord, I
प्रकाशित: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
द्वारा: Haldar, P, और अन्य
प्रकाशित: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
द्वारा: Howell, I, और अन्य
प्रकाशित: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
द्वारा: Erminia Ridolo, और अन्य
प्रकाशित: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
द्वारा: Kayser MZ, और अन्य
प्रकाशित: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
द्वारा: Ortega, H, और अन्य
प्रकाशित: (2014)

Mepolizumab for eosinophilic COPD
द्वारा: Sciurba, F, और अन्य
प्रकाशित: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
द्वारा: Osamu Matsuno, और अन्य
प्रकाशित: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
द्वारा: Yancey, S, और अन्य
प्रकाशित: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
द्वारा: Menzella F, और अन्य
प्रकाशित: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
द्वारा: Mirhojjat Khorasanizadeh, और अन्य
प्रकाशित: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
द्वारा: Gómez-Bastero Fernández A, और अन्य
प्रकाशित: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
द्वारा: Gunsoy, N, और अन्य
प्रकाशित: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
द्वारा: Laura J. Walsh, और अन्य
प्रकाशित: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
द्वारा: Alistair Cook, और अन्य
प्रकाशित: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
द्वारा: Howell, I, और अन्य
प्रकाशित: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
द्वारा: Imran Howell, और अन्य
प्रकाशित: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
द्वारा: Stephen G. Noorduyn, और अन्य
प्रकाशित: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
द्वारा: Francesco Menzella, और अन्य
प्रकाशित: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
द्वारा: Couillard, S, और अन्य
प्रकाशित: (2021)

Asthma in pregnancy: An update
द्वारा: Couillard, S, और अन्य
प्रकाशित: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
द्वारा: Shrimanker, R, और अन्य
प्रकाशित: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
द्वारा: Ortega, H, और अन्य
प्रकाशित: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
द्वारा: Gittins, A, और अन्य
प्रकाशित: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
द्वारा: Steven W. Yancey, और अन्य
प्रकाशित: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
द्वारा: Lisha Li, और अन्य
प्रकाशित: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
द्वारा: Kohei Somekawa, और अन्य
प्रकाशित: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
द्वारा: Andrew Menzies-Gow, और अन्य
प्रकाशित: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
द्वारा: Shrimanker, R, और अन्य
प्रकाशित: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
द्वारा: Oliver, ME, और अन्य
प्रकाशित: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
द्वारा: Carlos Martínez-Rivera, और अन्य
प्रकाशित: (2021-01-01)